#Switzerland #CGM System #Basel #CE Marking #FiberSense

Introduction

In a significant breakthrough for diabetes management, FiberSense AG has recently announced that its Continuous Glucose Monitoring (CGM) system has successfully acquired CE marking under the EU Regulation 2017/745. This pivotal step confirms the system's classification as a Class IIb medical device, enabling FiberSense to commence preparations for a commercial launch. This article delves into the implications of this achievement, outlining both the technical features of the CGM system and the company’s broader ambitions in the biomarker detection sector.

Overview of FiberSense CGM System

The FiberSense CGM system is designed to facilitate ongoing glucose monitoring for adults living with diabetes. Utilizing cutting-edge optical detection technology, the device measures glucose concentrations in subcutaneous interstitial fluid. This approach aims to provide a more accurate and user-friendly alternative to traditional glucose monitoring methods, allowing users to manage their condition more effectively in their daily lives.

Key Features and Innovations

One of the standout features of the FiberSense CGM system is its sensor's operational longevity, capable of continuous use for up to 28 days before replacement is necessary. This is made possible by combining advanced optoelectronic technology and durable materials that minimize wear and tear. Additionally, the detector and charger are designed for repeated use, enhancing the sustainability and cost-effectiveness of the device for users.

Official Remarks

Michael Tillmann, the Chief Executive Officer of FiberSense AG, expressed his enthusiasm regarding the CE marking, stating, "This certification marks a decisive milestone for FiberSense. After years of diligent development, we are now focused on ramping up production and market introduction." With the CE marking secured, FiberSense is transitioning from regulatory certification to market entry, preparing to upscale production, logistics, and customer service to meet the needs of targeted markets.

Future Developments

As FiberSense prepares to deliver its first products by the end of 2026, it also looks beyond its initial offerings. The CGM system functions as the first approved application within FiberSense's future biomarker monitoring platform, referred to as CxM. Although its current indication focuses on glucose monitoring for diabetic adults, the company is actively pursuing the development of additional products capable of measuring ketones, lactate, and cortisol among other biomarkers.

Strategic Goals

"The FiberSense CGM system represents the first regulated application of our long-term strategy," remarked Tillmann. The company's ambitious goals include exploring new avenues for continuous biomarker monitoring beyond glucose, ultimately seeking to develop a comprehensive platform that can support a wide array of analytes and applications. The foundation of this development relies on necessary scientific, clinical, and regulatory data.

Conclusion

The achievement of CE marking by FiberSense for its CGM system heralds a new era in diabetes management technology. As the company shifts its focus towards commercial launch, the implications for patients with diabetes could be profound, providing them with more effective tools for managing their health. FiberSense’s ongoing commitment to innovation indicates a promising future not only for its CGM system but also for its expanding portfolio of biomarker monitoring technologies.

For further inquiries regarding the FiberSense CGM system, please contact:
+49 (0)6026 942 121
[email protected]
www.fibersense-cxm.com